Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 1/2008

01-02-2008

Frequent point of care monitoring demonstrates the safety of low intensity warfarin therapy in Asian patients with mechanical heart valve

Author: Soumaya El Rouby

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2008

Login to get access

Excerpt

Genetic variants of the main cytochrome P-450 (CYP) and ethnicity may influence warfarin dosing. Chinese patients are reportedly more sensitive than Caucasians to the anticoagulant effect of warfarin. The use of the Point of Care Testing (POCT) and frequent monitoring of the international normalization ratio (INR) had facilitated measurements of essential coagulation parameters of warfarin therapy. To our knowledge, POCT has not been evaluated in clinical trials that underlay ethnic differences between different geographic regions. We have conducted a multi-center prospective trial to evaluate the safety of low warfarin dose, and the role of frequent INR measurements by POCT in Chinese patients. A total of 488 patients from 11 geographically diverse hospitals in China underwent implantation with CarboMedics aortic or mitral valve prosthesis (Sulzer Medica, Austin, TX). Patients received two consecutive doses of 2.5 mg warfarin at 24 and 72 h post-surgery, followed by a daily dose to maintain INR range of 1.5–2.5. The follow-up was performed weekly or biweekly and the INR was measured on fingerstick fresh whole blood, using the HEMOCHRON Signature Micro-coagulation system (ITC, NJ). The majority (99.3%) of Chinese patients who required prosthetic heart valve and warfarin therapy were <70 years old with a mean age of 45.28 ± 12. The mean follow-up duration was 86.8 ± 11.2 weeks (range 72–104 weeks). A total of 4,886 INR values were obtained with a mean INR in all 11 sites at 1.76 ± 0.50. The majority of INR values (67.8%, n = 3,312), was in therapeutic range (1.5–2.5), a moderate number was below range (26.2%, n = 1,281), whereas only 6.0% (n = 293) of INR value was above range. Mean daily maintenance dose was 2.5 ± 0.60 mg in all sites; a significant reduction from age-matched ACCP guideline for rest of the world (ROW) patients. Minor bleeding occurred in 42 cases, no patient required hospitalization. Major adverse events (4 cases) were lower than reported ROW data. The maintenance of antithrombotic efficacy with low warfarin requirement and narrow INR range in Chinese patients was independent of demographic factors and geographic locations. Frequent INR-POCT confirmed the safety of low dose warfarin requirements in Chinese patients. Monitoring by POCT may provide a mean to standardize warfarin monitoring across diverse geographic regions and therefore allow the analysis of ethnic variation in various subpopulations. …
Metadata
Title
Frequent point of care monitoring demonstrates the safety of low intensity warfarin therapy in Asian patients with mechanical heart valve
Author
Soumaya El Rouby
Publication date
01-02-2008
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2008
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-007-0146-1

Other articles of this Issue 1/2008

Journal of Thrombosis and Thrombolysis 1/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.